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_ \ h\traet - -\ Iler w hole or~an Iransplantation. donor 
hone marrow -tl~rlvtd cells mll/nlte out of Ihe graft Into the 
n·l·lpl~ntK kadlRl( 10 e,tablishment of chimrnsm. which is the 
firsl ~f~p towards Ihe subsequent induction of donor-specific 
lolerance. In roulme ImmunohistochemlC:t1 stainin~K mono-
<"innal anllbodlt~ ~peclfic for heterotopIc MHC alleles are 
lf~ed 10 Idenltly donor and recIpient cells. However. it Is 
difficult 10 delret Ihese cells usinR Ihis tecbnique. in long-
lerm ailol(rall rfrlplenlS who have a persIstently low donor 
n'lI population Imlcrochimensml. Because Interferon-gamma 
Dfc~KKKKIKK 1\ kno ... n to IOduce up~sslon oi MHC class I and 
<"iass 11 ceil ~urtlce molecules. we used this cytokine 12-48 h 
hdorr ,aUttll"f. It) tal"llilate the IdenlifiC2uon 01" donor and 
feClplent rell~ In I he lf~~ue~ oi aOlmals Inmsplanted with ei-
rller Ii'er !II III - ( 'II) or bone marrow tLE\V - BN)' In 
I""I(-Ierm allol(r:lll rf'Clptents. Ihe use oIIF:-';..,. for as briefly 
" f~ h prior 10 ,;tultice. results 10 marked uprell:ulation 01" 
IifD~ I ;lnu cia,s II ;lnlllZens. leadlOlllO easy Idenlification 01 
'J hlQul!oush ul\trlhUled low numben oi donor cells. 
~ fyeI"Dord~ - Interteron-",),: Chimemm; ;\1HC claS! I and 
,1;lSS II: eEgd~nls 
I'TRODL"CTIO:-t 
yy~I h;ne rropo,ed recentlv that solid organ transplan-
.. !tlOn ie:lds to a state or mixed allogeneic chimerism 
.\ IIh ,,\ lllcsprcaa mll.!ratlOn ot donor passenger leuko-
',tcs Into tt1C re~lplent ana a reciprocal trafficking of 
';llst (ctls IOlO I:1C transplanted organ (I). In humans. 
D:lFnor·~pecltlc ;:::155 ll-posltlve cells have been identified 
:1 thc skin. I\mon nodes. and blood at" HL\ mismatched 
: :C1plcnts. :,- -::9 vr alter renal transplantation (2), and 
:, lung as 23 " ~ alter lIver transplantation (3). In rats. 
mcer Ff.-:S06 ImmunosuppreSSIOn. donor MHC .:lass 
\,"CEPTED j :.:, 9~K 
~ c'urresoonaence should be addressed 10 Thomas E. 
c[:lrZJ. ,\1.0 .. 1':'.0 .• Dc:panment 01 Surgery, 3601 Fiflh Av-
001 
II-positive cells migrate out of the grafted liver into the 
recipient xs lymphoid and nonlymphoid organs (4). 
Similar observations have also been made in MHC dis-
parate mice. where multiple lineages of donor class 1 
and class II-positive cells were identifiable up to 375 
days after liver transplantation (5). 
Monoclonal antibodies directed against specific 
MHC hap 10 types are commonly employed to pheno-
type and characterize donor cells in MHC mismatched 
chimeric recipients. However, due to dwindling donor 
cell population and perhaps immunomodulation of 
donor MHC class I and class II surface molecules. im-
munohistochemIcal identification ot" these cells in long-
term allograft reCIpients becomes verv arduous, and 
the desired result is not always achieved. To facilitate 
their identification. we have used Interferon-gamma 
(I FN -')' ) to augment the expressIOn a f class I and class 
II antigens. 
INF-')' is mainly secreted by activated T cells (6) and 
is known to induce expressIOn at" MHC class I antigen 
on myocytes (7), endothelial and epithelial cells (8,9), 
lymphocytes (10), fibroblasts (II), and multi potent he-
matopOIetic precursor cell lines ( 12). I L also upregu1ates 
the expreSSIon of MHC class II molecules on endothe-
lial (12) and epithelial cells (13), on monocytes and 
macrophages (14,15), and on dendritic cells (16). The 
expressIOn 0 f class Il antigen-associated invariant 
chain is also upregulated by IFN-')' (17). We repon here 
the use or IFN-')' to boost MHC class I and class 11 ex-
pression on chimenc donor cells in long-term allograft 
recipients. 
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MATERIAL. METHODS, A:"ID RESULTS 
In Mice 
livers from C57Bl/lO donors (BIO, H-2k b , I-A b ) 
were transplanted into CJH (H-2kk. I-P) recipients 
by a method described previously (3). Between 1 h 
and more than 400 days after transplantation each 
animal in the experimental group was treated intraper-
itoneally (lP) with 4 x 105 U of recombinant IFN.,. 
(rIFN.,.. Schering-Plough, Kenilworth. NJ). Animals 
were sacrificed 48 h after rIFN--y treatment and vari-
ous lymphoid and nonlymphoid organs harvested. 
Liver recipients (1 h-400 days> OlTx) without rlFN.,. 
treatment were used as controls. Harvested organs 
(hean. liver. pancreas. kidney. small bowel. adrenal 
gland. lungs, tongue. spleen. thymus. cervical, and 
mesenteric lymph nodes) were embedded in Tissue-
Tek" (O.C.T Compound. Miles. f~FI snap frozen in 
liqUId nitrogen. and sectioned on a Cryostat. The sec-
tions were stained with a panel of primarY monoclonal 
antibodies (mAb), the results of which are detailed 
elsewhere (5). Our paper reports t he use 0 f donor-
specific anti-class 1 mAb (mouse fgd~ • .;lone AF6-
88.5. PharMingen. San Diego. CAl and antI-class II 
mAb (mouse IgG 2a , done AF6-120.1. PharMingen. 
San Diego. CAl on recipient's spleens (90 days> 
OlT.x). Isotype-matched irrelevant mAb was used as 
negative control. Frozen sections were stained by an 
indirect avidin-biotin immunoperoxldase method as 
descnbed preVIously (5). Brierlv, ,m dned sections were 
tixed m acetone for mm, endogenous biotin was blocked 
with sequential treatment wah aVidin and biotm block-
ln~ reagent (Vector LaboratOrIes. Inc .. Burlingame. 
CAl. and then incubated for 45 mm with blotmylated 
primary mouse mAb. Endogenous pero~ldase actIvity 
was then quenched WIth 0.61r.o H,01, and finally incu-
bated with streptavldin conjugated peroxidase complex 
for 30 min (Boehringer Mannhelm. Indianapolis. IN). 
The reaction product was developed With )·ammo-9-
ethylcar-bazole (AEc). and after coumerst3.lning with 
hematoxylin. mounted with crystal moum (Biomeda 
Corp .• Foster City, CAl. Sections were evaluated for 
specllic cell staming with a Nlkon Microphot-FX light 
rTIlcroscope. 
In spleens of comrol ammais (90 davs > OLTx). 
it was very difficult to identlfv either donor class I 
\Fig. 1.1) or class II-positive cells (Fig. kl. Cell stain-
ing was trail. and the frequencv of wealdv staIned do-
nor cells was very low. Additionallv, donor MHC class 
I staIning was always weaker than class 11 (Fig. la,c). 
These findings are In accord with our earlier observa-
tions In rats. in which we showed that both the num-
ber and the intensity of staining oi donor celis was low 
in long-term allograit reapients (4). However. 48 h 
after r1FN.,. treatment brightly stained donor-class 1 
(Fig.lb)andclass II-positivecells(Fig.ld)wereeas-
ily identified in the recipient's spleen. In addition to in-
tensity, the frequency of MHC positive donor cells was 
also markedly increased. Similar observations were 
also made in other lymphoid and nonlymphoid organs 
(data not shown). 
In Rats 
2_5 X 108 bone marrow cells (BMTx) were traDS-
planted from male lEW (RTll) donors to male Brown 
Norway (BN, RTl") recipients, which were immuno-
suppressed with 1 mg/kg/day of FK506 for 14 days, 
and once a week thereafter for 160 postoperative days. 
At 12,24, and 48 h before sacrifice, animals in the ex-
perimental group were treated IP with a single dose of 
2 x 107 U/kg of rIFN--y (Genentech. Inc., San Fran-
cisco, CA), and various lymphoid and nonlymphoid 
organs were harvested and processed as mentioned-
elsewhere (4). Control animals received BMTx and 
FK506, without rlFN--y. Skin and cervical lymph nodes 
were recovered from some experimental animals, prior 
to rIFN--y treatment, to serve as internal controls. In 
this study the mAb L-21-6 (mouse anti-rat IgG,) was 
used, which specifically recognizes the invariant chain 
of the donor MHC class II molecule. but not that of 
the recipient (18). Isotype-matched irrelevant primary 
mAb was used as a negative control. Cryosections wen: 
stained by indirect immunoperoxidase method using 
preformed avidin-biotin kit (Vector laboratories. Inc •• 
Burlington. CAl, according to a method described pre-
viously (4). The coloration was developed with AEe. 
counterstained with Harris's hematoxylin and mounted 
with crystal mount. 
Weakly L-21-6-positive donor cells in very low num-
bers were identified in the spleens of control animals 
given BMTx under FK506 immunosuppression (Fig. Ie). 
However. as early as 12 h after rIFN-')' treatment. 
strong class II-positive donor cells were identified at a 
very high frequency in the recipient's spleen (Fig. 1 n. 
Similar upregulation of class II was also observed 24 
and 48 h after rlFN--y treatment in the spleen and other 
organs of the recipient (data not shown). Funhermore. 
cervical lymph nodes and skin obtained from the same 
BMTx recipients before and after rIFN--y treatment 
showed marked upregulation of donor class II after 
but not before rlFN--y enhancement (data not shown). 
Additionally, treatment with supernatant from 3-day 
~lo cultures. which has LFN-')' among other eyro-
kines (19). aiso leads to marked. upregulation of donor 
class 11 in the recipientxs organs (data not shown). 
CONCLUSIONS 
The results of these experiments show that !FN....,-
can be suc:a:ssfuUy used to boost the expression of IaIe 
IFN""Y facilitates donor cell identification in transplant recipients. 0.5. KOUUTT AND D.O. PlPELEEU 003 
Fig. I. IndIrect immunoperoXldase staming of spleen sections from CJH recipient of 810 liver (90 days> OLTx), without 
(a) and with (b) r I FN-..,. treatment. The sections were stained with donor'specific anti-class I mAb. Note the intensely stained 
Jonor class I·posltive cells (T) in (b) but nOl In (a). Figure l(c,d): Indirect immunoperoxidase staming of spleen sections from 
reoplent (C) H) oi B 10 liver (90 days> OL Tx), incubated with donor'specific anll-class 11 !nAb. without (c) and Mth (d) rlFN-y 
treatment. Donor class lI,posltive cells stained with red reaction product (T) are much more evtdent in (d) but not in (c). Fig. 
ure l(e.f): sections of spleen from BN rmpient oi LEW bone marrow 060 days> BMTx), without (e) and with (f) rIFN-y 
treatment. The sections werestaiDed with i·O1~ mAb (which reacts with invanant chain of LEW MHC class 11. but not BN). 
Doaor ciasa !I·poIlove eeils lhatabow me red reacaon product (T) arc much brilhtcr and more frequent tn (£) than in (e). Sec:-
tions were stained with indirecl immua~ meUlod. (Oriliaal mqaifac:atioft x 260). 121 
MHC class I and class II molecules in chimeric recipi-
ents, making it possible for the first time to extensively 
phenotype and characterize the lineages of these cells 
in aUograft recipients. The question may be asked if 
IFN-'Y administration is inherently immunomodulat-
ing and therefore an artifact in the system. However, 
the experimental endpoints are cell localization not 
their immunologic consequences. Presumably, the cells 
are in place by the time IFN--y is administered. We 
therefore believe that IFN--y treatment before sacrific-
ing the animals may allow a much greater delineation 
of the true magnitude of the so-called microchimerism 
in a number of experimental models. We see no way 
in which IFN--y could significantly influence either the 
extent or constituency of chimerism because rlFN--y 
treatment for as brief as 12 h can lead to MHC class 
II upregulation. 
REFERL"'iCES 
l. Starzl. TE.; Demetns. A.J.; Murase. N.: lldstad. S.: 
Ricordi c.; Trucco. M. Cell migration. chImerism. and 
graft acceptance. Lancet 339: I 579-1 582; 1992. 
2 .. Starz.1, T.E.; Demetrls, A.J.; Trucco, l\t.: Zecvi. A.; 
Ramos. H.; Terasaki. P.; Rudert. \v'A.; et al. Chime-
rism and donor speCIfic nOnmlctivity 27 to 29 years after 
kidney aliotransplantauon. Transplantauon .55: 1272-1277; 
1993. 
3. Starz!. TE.: Demetris. A.1.; Trucco. M.; Ramos. H.; 
Zeevi. A.: Rudert. W.A.: Kocoua. M.: et al. Systemic 
chimerISm In human female reCIpIents of male livers. 
Lancet H0:876: 1992. 
.1, Demetns. A.1.: ~turaseK N.: Fuiisakl. S.; Fung. J.1.; 
Rao. A.S.: Starzl. T.E. Hematol\'mphold cell trafiick-
:ng. mlcrochimensm. and GVH reactions alter liver. 
bone marrow. and heart transplantation. Transplant 
Proc. 25:3337-3344: 1993. 
). Qian. S.; Demems. A.J.; Murase. N.: Rao. A.S.; Fung 
1.1.; Starz..l. TE. Murine liver allograft transplantation: 
? I? Tolerance and donor cell chimerISm. Hepatology (In 
press,. 
6. Halloran. P.F.: Wadgymar A.: Autenreld. P. The regu-
lation of e . ..:presslOn of major histocompatibility complex 
products. Transplantation 41 :413; 1986. 
- Kalovtdouris. A.E. The role of cytokines In polymyosl-
[IS Interferon-.., induces class 11 and class I major histo· 
compatibility complex antigen expression on cultured 
human muscle cells. J. Lab. Clin. Med. I:O(2l:244-1 SI: 
1':192. 
~I Paineau. J.; Priestly. c.; fabre. J.; Chevalter. S.; van 
der Meide, P.; Schellekens, H.; Jacques. Y.; et al. Effect 
of recombinant interferon gamma and interleukin-2 and 
of a monoclonal antibody against interferon gamma on 
the rat immune response against hean allografts. J. Heart 
Lung Transplant. 10(3):424-430; 1991. 
9. Doukas, J.; Pober. J.S. IFN.,. enhances endothelial ac-
tivation by tumor necrosis factor but not IL-l. J. Immu-
nolo 145(6):1727-1733; 1990. 
10. Walrand, F.; Picard, F.; McCullough, K.; Maninod S.; 
Levy, D. Recombinant bovine Interferon.,. enbances ex-
pression of class I and class 11 bovine lymphocyte anti-
gens. Vet.lmmunol.1mmunopaIbol. 22(4):279-283; 1989. 
11. Morris, A.G.; Ward, G.A.; Bateman. W.J. Instability 
of expression of major histocompatibility antigens in fi-
broblast expressing activated ras oncogenes: Constitu-
tive and Interferon--y induced class I and class II antigens 
in a series of clonal isolates of murine fibroblasts uans-
formed by v-Ki-ras. Br. J. Cancer 60(2):211-215; 1989. 
12. Takemura, Y.; Koide. Y.; Kawabata. M.; Kitajima. S.; 
Ohba. C.; Suzuld, H.; Seldguchi, S. Synergistic enhance-
ment of class I major histocompatibility complex anti-
gen expression in K562 cells induced by recombinant 
human Interferon· gamma and tumor necrosis factor in 
combination. Exp. Hematol. 17(7)795-799; 1989. 
13. Berrih, S.; Arenzana-Seisdedos. F.: Cohen. S.; Devos, 
R.; Charron. D.; Virelizier. J. Interieron--y modulates 
HLA class 11 antigen expression on cultured human thy-
mic epithelial cells. J. Immunol. 135(2): 1165-1171; 1985. 
14. Virelizier. J.; Perez. N.: Arenzana·Seisdedos. F.; Devos, 
R. Pure interferon gamma enhances class II HLA anti-
gens on human monocyte cell lines. Eur. J. Immunol. 
14:106-\08; 1984. 
15. Steiniger. B.; Sickel. E. Class II :-'1HC molecules and 
monocytes/macrophages in the respiratory system of 
conventional. germ·free and Interferon-gamma-treated 
rats. Immunobiology 184(4-5):295-310: 1992. 
16. Skoskiewicz. M.J.; Colvin. R.B.; Schneeberger E.E.: 
Russell. P.S. Widespread and selective induction of ma-
jor histocompatibility complex-determined antiKens in 
vivo by gamma interferon. J. Exp. Med. 162(5): 1645-
64; 1985. 
17. Pessara. U.; Momburg, F.; Koch. N. Cooperative effect 
of Interferon-gamma and tumor necrosis factor-alpha 
on the induction of the class II antigen·associated invari· 
ant chain. Eur. J. Immuno!. 18(11):1719-26; 1988. 
18. Murase. N.: Demelris. A.J.; Matsuzaki. T.; Yagihasi. 
A.; Todo. S.; Fung, J.J.; Starzl. TE. Long survival in 
rats after multivisccrai vs. isolated small bowel allotrans-
plantation under FK506. Surgery 110:87; 1991. 
19. Falcoff. R. Some properties of virus and immune-
induced human lymphocyte Interierons. J. Gen. Virol. 
16:251-253; 1972. 
